Search clinical trials for: AZD1722 and Midazolam

Total 269834 results

Ardelyx

Completed

To Evaluate the Effect of AZD1722 on the Pharmacokinetics of Oral Midazolam in Healthy Volunteers

Healthy Volunteers

United States
Ardelyx

Completed

AZD1722 Open Label, Absorption Distribution Metabolism and Excretion Study

Healthy Volunteers

United Kingdom
Ardelyx

Completed

Dose Finding Study to Treat High Phosphate Levels in the Blood.

Hyperphosphatemia

United States, Poland, United Kingdom, Slovakia
Ardelyx
AstraZeneca

Completed

A Study in CKD Patients With Type 2 Diabetes Mellitus and Albuminuria

Type 2 Diabetes Mellitus | Chronic Kidney Disease

United States
Ardelyx
AstraZeneca

Completed

Pharmacodynamic Study of AZD1722 in End-stage Renal Disease Patients on Hemodialysis

End Stage Renal Disease | ESRD | Chronic Kidney Disease Stage 5

United States
Ardelyx

Completed

A Long-Term Safety Study of Tenapanor for the Treatment of IBS-C (T3MPO-3)

Constipation Predominant Irritable Bowel Syndrome

United States
Ardelyx

Completed

A 26-Week Study to Evaluate the Efficacy and Safety of Tenapanor in IBS-C (T3MPO-2)

Constipation Predominant Irritable Bowel Syndrome

United States
Ardelyx
AstraZeneca

Completed

Safety, Tolerability, Pharmacokinetics and Pharmacodynamic of AZD1722 in Healthy Male and Female Japanese Subjects

Healthy Volunteer

United States
Ardelyx

Completed

A 12-Week Study With a 4-Week Randomized Withdrawal Period to Evaluate the Efficacy and Safety of Tenapanor for the Treatment of IBS-C (T3MPO-1)

Constipation Predominant Irritable Bowel Syndrome

United States
Ardelyx

Completed

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RDX5791 in Healthy Volunteers

Healthy
Ardelyx

Completed

An 8-Week Study to Evaluate Tenapanor in the Treatment of Hyperphosphatemia in End-Stage Renal Disease Patients on Hemodialysis (ESRD-HD)

Hyperphosphatemia

United States
Ardelyx

Completed

The Efficacy of AZD1722 in Constipation Predominant Irritable Bowel Syndrome (IBS-C)

Constipation Predominant Irritable Bowel Syndrome

United States
Imperial College London
AstraZeneca; University of Oxford

Active, not recruiting

A Study to Determine Safety and Immunogenicity of the Candidate COVID-19 Vaccine AZD1222 Delivered by Aerosol in Healthy Adult Volunteers (COVAXAER01)

Covid19 | SARS-CoV-2 Infection

United Kingdom
Ardelyx

Completed

D5611C00003 - Food Interaction Study With AZD1722 Tablet in Healthy Subjects

Healthy Volunteers Food Interaction Study

United States
AstraZeneca
Covance; Iqvia Pty Ltd

Withdrawn

AZD1222 Vaccine for the Prevention of COVID-19

COVID-19

Russian Federation
AstraZeneca
RTI Health Solutions

Completed

EU Secondary Data Post-Authorisation Safety Study of AZD1222 (D8111R00006)

COVID-19, Vaccine Adverse Events of Special Interest

Netherlands, Spain, United Kingdom
AstraZeneca

Completed

Study to Investigate the Safety Profile of AZD4721 After Single Doses at Different Dose Levels

Safety,Plasma AUC and Cmax, Plasma AUC 0-t, t1/2λz, and Tmax

United Kingdom
Federal University of Espirito Santo
Instituto René Rachou/Fiocruz; Escola Nacional de Saúde Pública Sérgio Arouca... and other collaborators

Recruiting

EFFECTIVENESS, SAFETY AND IMMUNOGENICITY OF THE HALF DOSE OF THE VACCINE ChadOx1 nCoV-19 (AZD1222) for COVID-19

SARS-CoV-2

Brazil
Albert B. Sabin Vaccine Institute
Stanford University; Aga Khan University; Oswaldo Cruz Foundation

Completed

Immunogenicity and Safety of Fractional Booster Dose of COVID-19 Vaccines Available for Use in Pakistan/Brazil: A Phase 4 Dose-optimizing Trial

COVID-19

Brazil, Pakistan
Ardelyx

Completed

Safety, Tolerability, and Pharmacodynamics of RDX5791 in Healthy Volunteers

Healthy
AstraZeneca

Completed

An Open Label, Single Centre Mass Balance C14 Study in Patients With Acute Myeloid Leukaemia (AML)

Acute Myeloid Leukaemia

United Kingdom
AstraZeneca
Quintiles, Inc.

Completed

This is a Study to Evaluate the Safety, Tolerability and Pharmacokinetics (PK) of AZD9742 After Single IV Doses in Healthy Subjects

Healthy

United States
AstraZeneca

Completed

AZD1152 in Patients With Advanced Solid Malignancies

Tumors

United States
Humanity & Health Medical Group Limited

Completed

Antibody Response to COVID-19 Vaccines in Liver Disease Patients

Chronic Liver Disease

Hong Kong
Chang Gung Memorial Hospital

Recruiting

Immunogenicity of COVID-19 Vaccine on Heterologous Schedule

Healthy | Covid-19 | Vaccine | Immunogenicity | Reactogenicity

Taiwan
Peking University
AstraZeneca

Recruiting

Phase 1 Trial of AZD6422 in CLDN18.2+ GI Tumors

Gastrointestinal Tumors

China
AstraZeneca
Iqvia Pty Ltd

Completed

Study of AZD1222 for the Prevention of COVID-19 in Japan

COVID-19

Japan
R-Pharm
AstraZeneca; Russian Direct Investment Fund; The Gamaleya National Center of...

Completed

Study in Adults of AZD1222 and rAd26-S Administered as Heterologous Prime-Boost Regimen for the Prevention of COVID-19

COVID-19

Russian Federation
Federal University of Espirito Santo
Instituto René Rachou/Fiocruz

Recruiting

COVID-19 VACCINE SAFETY AND EFFECTIVENESS

SARS-CoV-2 Infection

Brazil
Oxford University Hospitals NHS Trust
University of Manchester; The Christie NHS Foundation Trust; Early Phase Cancer...

Completed

AZD1152 in Diffuse Large B-cell Lymphoma

Lymphoma

United Kingdom
AstraZeneca

Completed

Safety, Tolerability, PK and Efficacy of AZD1152 in Patients With Relapsed Acute Myeloid Leukemia

Myeloid Leukemia

United States, Italy, Netherlands, France
AstraZeneca

Completed

Safety, Tolerability and PK of AZD1152 in Patients With Relapsed Acute Myeloid Leukaemia (AML)

Acute Myeloid Leukaemia

Japan
AstraZeneca

Terminated

AZD1152 in Patients With Advanced Solid Malignancies-Study 1

Solid Tumors

Netherlands
AstraZeneca

Terminated

AZD1152 in Patients With Advanced Solid Malignancies-Study 3

Solid Tumours

United Kingdom
AstraZeneca

Completed

Study to Investigate Safety, Tolerability and Pharmacokinetics of a Single Ascending Dose of AZD1704

Pain

United Kingdom
Shabir Madhi
AstraZeneca

Completed

Effectiveness of Covid-19 Vaccination in Eswatini Against SARS-CoV-2 Associated Hospitalization and Death

COVID-19 | Pneumonia, Viral

Swaziland
AstraZeneca

Completed

A Study in Healthy Volunteers to Assess Safety and Blood Levels of AZD9742 After Multiple Doses Over 14 Days

Healthy

United States
AstraZeneca

Terminated

Assess Safety, Tolerability and Pharmacokinetic (PK) of AZD1704 in Healthy Japanese Male and Non-Fertile Female Volunteers

Healthy Volunteers

United Kingdom
AstraZeneca

Completed

Study to Investigate the Activity of AZD5122 When Given as a Single Dose to Healthy Male Subjects

Healthy

United Kingdom
AstraZeneca
Iqvia Pty Ltd

Completed

Phase III Double-blind, Placebo-controlled Study of AZD1222 for the Prevention of COVID-19 in Adults

COVID-19 | SARS-CoV-2

United States, Chile, Peru
AstraZeneca

Withdrawn

Study in Healthy Males to Assess Distribution, Metabolism, and Excretion of Radio-labelled AZD9742 Administered as a 2-hour Infusion

Healthy

United States
AstraZeneca

Completed

AZD9742 Single and Multiple Ascending Dose Study in Healthy Male and Female Japanese Subjects

Healthy

United States
AstraZeneca

Completed

Study to Investigate Safety, Tolerability and Effect of Multiple Dosing With AZD 4721 and/or With AZD 5069

Chronic Obstructive Pulmonary Disease (COPD).

United Kingdom
Medigen Vaccine Biologics Corp.

Completed

A Study to Evaluate Immunogenicity and Safety of MVC-COV1901 Compared With AZD1222 in Adults Aged 18 Years and Above

COVID-19 Vaccine

Thailand
Medigen Vaccine Biologics Corp.

Completed

A Study to Evaluate Immunogenicity and Safety of MVC-COV1901 Vaccine Compared With AZD1222

COVID-19 Vaccine

Paraguay
Medigen Vaccine Biologics Corp.

Completed

A Study to Evaluate Immunogenicity and Safety of MVC-COV1901 Compared With AZD1222 Against COVID-19 in Adults

Covid19 Vaccine

Paraguay
AstraZeneca

Completed

Assessing the Safety and Tolerability of a Single IV Dose of AZD9742 in Healthy Elderly Male and Female Subjects

Healthy | Elderly | Tolerability

United States
AstraZeneca

Terminated

A Study of AZD1222, a Vaccine for the Prevention of COVID-19 in Immunocompromised Adults (VICTORIA)

COVID-19, SARS-CoV-2

Thailand, Ukraine
Ardelyx

Completed

To Assess the Effect of AZD1722 on the Pharmacokinetics of Cefadroxil in Healthy Volunteers

Healthy Volunteers

United States
Ardelyx

Completed

A Phase 3 Study of Tenapanor to Treat Hyperphosphatemia in ESRD Patients on Dialysis

Hyperphosphatemia

United States

3

Subscribe